A 60-Year-Old Man with Prostate Cancer

home / case-based-peer-perspectives / a-60-year-old-man-with-prostate-cancer

Gordon A. Brown, DO, presents the case of a man with prostate cancer, reviews available treatment options, and discusses data on combination androgen deprivation therapy/apalutamide in patients with metastatic castration-sensitive prostate cancer.

Introduction: A 60-Year-Old-Man with Prostate Cancer

EP. 1: Introduction: A 60-Year-Old-Man with Prostate Cancer

Gordon A. Brown, DO
July 19th 2022

Gordon A. Brown, DO, presents the profile of a 60-year-old man with prostate cancer.

An Expert Commentary on the Patient Profile and Considerations for Treatment and Management of Prostate Cancer

EP. 2: An Expert Commentary on the Patient Profile and Considerations for Treatment and Management of Prostate Cancer

Gordon A. Brown, DO
July 19th 2022

An expert comments on the patient profile and offers insights into how he approaches treatment and management of prostate cancer.

Available Single-Agent and Combination Therapies for mCSPC

EP. 3: Available Single-Agent and Combination Therapies for mCSPC

Gordon A. Brown, DO
July 19th 2022

Dr Gordon Brown provides an overview of single-agent androgen deprivation therapy (ADT) and other regimens that may be used in combination with ADT, including androgen receptor (AR) inhibitors, for treatment of mCSPC.

Efficacy Data on Combination ADT/Apalutamide from the TITAN Trial and Real-World Analyses

EP. 4: Efficacy Data on Combination ADT/Apalutamide from the TITAN Trial and Real-World Analyses

Gordon A. Brown, DO
July 19th 2022

A comprehensive review of efficacy data on combination therapy with ADT and the AR inhibitor apalutamide in patients with mCSPC.

Safety of Combination ADT/Apalutamide and Management of Adverse Events

EP. 5: Safety of Combination ADT/Apalutamide and Management of Adverse Events

Gordon A. Brown, DO
July 19th 2022

Gordon A. Brown, DO, comments on adverse events observed after combination ADT/apalutamide treatment and how they might be managed.

A Comparison of AR Inhibitor Safety and Efficacy and Factors That Impact mCSPC Treatment Selection

EP. 6: A Comparison of AR Inhibitor Safety and Efficacy and Factors That Impact mCSPC Treatment Selection

Gordon A. Brown, DO
July 19th 2022

A comparison of the safety and efficacy of available AR inhibitors and a discussion of factors that impact treatment selection in mCSPC.

Unmet Needs and Future Directions for Patients with Metastatic CSPC

EP. 7: Unmet Needs and Future Directions for Patients with Metastatic CSPC

Gordon A. Brown, DO
July 19th 2022

Dr Gordon Brown closes his discussion on mCSPC by highlighting unmet needs in the field and ongoing initiatives that may address these needs.

© 2024 MJH Life Sciences

All rights reserved.